Pharma Pulse 12/23/24: The Impact of RAIN RFID, Treatment Advances for Alzheimer Disease Provide Hope & more

Peer Exchange: The Impact of RAIN RFID

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, alongside a panel of experts, discussed the role of radio frequency identification (RFID) technology in the pharmaceutical and healthcare sectors. RFID is a technology that utilizes radio waves to automatically collect and transfer data, providing efficient tracking and tracing of products. This discussion covers the potential and challenges of RFID in the industry.

The panel consisted of Matt Campasano, Managing Director, Criterion Consulting; Sean O’Hearen; Founder & Principal Consultant, 1^st Line Partners; Tim Marsh, Founder & Head of Strategy, MDB; and Bahar Aliakbarian, PhD, Associate Professor, Sr. Director of R&D, Axia Institute (at Michigan State University).

Each expert brought unique perspectives on RFID’s applications, including brand protection, traceability, and supply chain efficiency.

Treatment Advances for Alzheimer Disease Provide Hope

New mechanisms of action are proving more effective than ever, offering slowed progression.

Lilly Cements Weight Loss Lead After Novo Trial Setback

The fierce battle between weight-loss drug makers has led to sky-high Wall Street expectations, with investors anticipating new medicines that are incrementally more powerful and easier to take.

U.S. FDA Approves Pfizer’s BRAFTOVI^® Combination Regimen

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI^® (encorafenib) in combination with cetuximab (marketed as ERBITUX^®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.ⁱ The indication was approved based on a statistically significant and clinically meaningful improvement in response rate and durability of response in treatment-naïve patients treated with BRAFTOVI in combination with cetuximab and mFOLFOX6 from the Phase III BREAKWATER trial. Continued approval for this indication is contingent upon verification of clinical benefit. This accelerated approval is among the first in the industry to be conducted under the FDA’s Project FrontRunner, which seeks to support the development and approval of new cancer drugs for advanced or metastatic disease.

Miranda Schmalfuhs on LinkedIn

Part 2 of my talk with Peter Ax, CEO of UpScriptHealth, is live! During this part, we dive into how recent #DEA extensions will impact new #telehealth treatment modalities and patient populations!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs